![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Thursday, October 19, 2000 8:45:14 PM
As one of the first practitioners in the new field of Phenomics, we
hold distinct advantages.
Our advantages are:
1.We have developed and patented a proprietary biochemical
reagent (TruSeqTM) for high-throughput genetic analysis using
a DNA chip based or electrophoresis based platform
technology.
2.We are forming strategic alliances with other genomics and
pharmacogenomics companies, for access to raw materials and
intellectual property, lowering our R and D basis.
3.We are assembling a proprietary collection of LIMS (FEMSTM)
and heuristic software tools for a revolutionary data mining
process specially suited for Phenomics applications.
4.We are compiling unique SNP databases for target phenotypes
and diseases. Our proprietary data mining routines capitalize
on the newness of high-throughput genotyping technology and
the recent completion of the human genome project.
Copyright DNAprint genomics © 2000
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM